Asthma: Chronic treatment with inhaled long-acting Beta-2 agonists: Benefits and risks
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2000 May 13;355(9216):1675-79 Randomized Controlled Trial
IN asthma The Use of
inhaled beta2 agonist, long-term fixed regular use
As Treatment, Chronic
Is better Than
placebo and inhaled beta2 agonist, as needed
To improving diurnal peak expiratory flow. No differences in the annual rate, timing, or duration of exacerbations.
Chest. 1999 Sept;116(3):595-602 Randomized Controlled Trial
IN asthma The Use of
inhaled beta2 agonist, long-term fixed regular use
As Treatment, Chronic
Is better Than
placebo and inhaled beta2 agonist, as needed
To improving FEV1 and symptoms. No differences in the annual rate, timing, or duration of exacerbations.
Am J Med. 2010 Apr;123(4):322-8.e2 Meta-Analysis
IN asthma The Use of
inhaled long-acting beta2 agonist, long-term regular use
As Treatment, Chronic
Is worse Than
placebo or inhaled corticosteroids alone
To prevent asthma-related intubation or death: they increase the risk by 2 folds OR 2.10
Ann Intern Med. 2006 Jun 20;144(12):904-12. Epub 2006 Jun 5 Meta-Analysis
IN asthma The Use of
inhaled long-acting beta2-agonists
As Treatment, Chronic
Is worse Than
placebo
To prevent exacerbations: they increased hospitalisations by asthma exacerbation (OR, 2.6; absolute increase 0.7%) and life-threatening exacerbations (OR, 1.8)